GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guangdong Jiaying Pharmaceutical Co 002198.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

3.24

+1.57%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥383.8m

FY2016FY2025

Net income

CN¥30.5m

FY2016FY2025

Free cash flow

−CN¥100.9m

FY2016FY2025

Shareholders' equity

CN¥717.9m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥383.8mCN¥376.2mCN¥533.2mCN¥659.2mCN¥574.7mCN¥544.7mCN¥500.5mCN¥537.0mCN¥468.1mCN¥450.0m
Gross profitCN¥230.0mCN¥224.3mCN¥346.9mCN¥430.0mCN¥431.5mCN¥396.6mCN¥393.3mCN¥392.3mCN¥342.5mCN¥344.0m
Research and developmentCN¥9.0mCN¥6.8mCN¥10.1mCN¥15.3mCN¥14.4mCN¥9.4mCN¥14.4mCN¥12.4mCN¥10.1mCN¥11.2m
Operating incomeCN¥44.7mCN¥25.3mCN¥40.5mCN¥53.9mCN¥5.4mCN¥24.1m−CN¥110.7mCN¥43.3m−CN¥206.9mCN¥66.7m
Net incomeCN¥30.5mCN¥20.6mCN¥34.3mCN¥43.9mCN¥1.5mCN¥19.8m−CN¥122.2mCN¥35.9m−CN¥214.8mCN¥55.2m
Diluted earnings per share0.060.040.070.090.000.04-0.240.07-0.420.11

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥849.2mCN¥838.8mCN¥847.6mCN¥846.7mCN¥807.3mCN¥808.4mCN¥855.9mCN¥889.6mCN¥876.6mCN¥1.10bn
Cash and short-term investments—CN¥336.1mCN¥334.0mCN¥234.1mCN¥239.4mCN¥142.2mCN¥122.3mCN¥114.9mCN¥82.0mCN¥73.3m
Total liabilitiesCN¥131.3mCN¥80.6mCN¥84.6mCN¥118.2mCN¥122.9mCN¥125.4mCN¥192.8mCN¥104.2mCN¥126.8mCN¥114.4m
Debt—CN¥3.3mCN¥4.4mCN¥5.8mCN¥31.1mCN¥20.2mCN¥96.8mCN¥19.0mCN¥40.0mCN¥19.9m
Shareholders' equityCN¥717.9mCN¥758.2mCN¥763.0mCN¥728.4mCN¥684.5mCN¥683.0mCN¥663.2mCN¥785.4mCN¥749.8mCN¥984.9m
Shares outstanding510m518m509m508m523m510m506m508m508m507m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥9.0mCN¥60.8mCN¥98.5mCN¥27.2mCN¥51.8mCN¥96.9mCN¥13.0mCN¥62.1mCN¥30.6mCN¥53.1m
Capital spending−CN¥109.9m−CN¥38.7m−CN¥5.1m−CN¥2.7m−CN¥2.3m−CN¥11.7m−CN¥18.8m−CN¥8.9m−CN¥18.4m−CN¥12.0m
Free cash flow−CN¥100.9mCN¥22.1mCN¥93.4mCN¥24.4mCN¥49.5mCN¥85.2m−CN¥5.9mCN¥53.2mCN¥12.2mCN¥41.1m
Dividends paid—−CN¥25.4m−CN¥445−CN¥454,167−CN¥1.0m−CN¥3.8m−CN¥3.5m−CN¥1.3m−CN¥21.9m−CN¥1.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥42.8mCN¥122.9mCN¥90.3mCN¥94.5mCN¥77.3mCN¥121.6mCN¥116.6mCN¥79.4m
Gross profitCN¥31.8mCN¥56.4mCN¥64.5mCN¥41.1mCN¥43.2mCN¥81.3mCN¥75.2mCN¥49.0m
Operating income−CN¥17.8mCN¥13.9mCN¥17.8mCN¥2.1mCN¥4.2mCN¥19.3mCN¥20.5m−CN¥1.7m
Net income−CN¥25.4mCN¥12.5mCN¥8.7mCN¥1.7mCN¥4.7mCN¥15.4mCN¥17.7m−CN¥2.8m
Diluted earnings per share-0.050.020.020.000.010.030.03-0.01
Cash from operations———−CN¥45.0m−CN¥11.0m−CN¥11.0mCN¥43.0m−CN¥1.0m
Capital spending−CN¥5.0m−CN¥7.0m−CN¥63.0m−CN¥27.0m−CN¥11.0m−CN¥7.0m−CN¥4.0m−CN¥12.0m
Free cash flow———−CN¥72.0m−CN¥22.0m−CN¥18.0mCN¥39.0m−CN¥13.0m
Total assetsCN¥847.3mCN¥892.8mCN¥849.2mCN¥774.7mCN¥790.7mCN¥812.6mCN¥838.8mCN¥796.0m
Cash and short-term investments———CN¥127.9mCN¥206.1mCN¥268.5mCN¥336.1mCN¥297.0m
Debt————CN¥9.3m—CN¥3.3m—
Shareholders' equityCN¥704.9mCN¥730.4mCN¥717.9mCN¥709.0mCN¥715.9mCN¥724.1mCN¥758.2mCN¥740.5m

Financial ratios

Data as of 21 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin59.9%59.6%65.1%65.2%75.1%72.8%—
Operating margin9.9%6.7%7.4%7.8%1.2%5.0%—
Net margin7.9%5.5%6.4%6.7%0.3%3.6%—
Return on equity4.2%2.7%4.5%6.0%0.2%2.9%—
Return on assets3.6%2.5%4.0%5.2%0.2%2.5%—
Free cash flow yield—3.6%5.9%1.6%3.0%5.8%0.8%
Revenue growth2.0%-29.5%-19.1%14.7%5.5%8.8%—
Earnings growth47.9%-39.9%-21.9%2874.0%-92.6%-116.2%—
Current ratio5.22x12.15x11.76x6.72x5.57x4.80x—
Debt to equity—0.00x0.01x0.01x0.05x0.03x0.15x
Equity ratio84.5%90.4%90.0%86.0%84.8%84.5%—
Interest coverage201.38x645.04x1172.80x105.09x6.42x6.70x—
R&D as a share of sales2.4%1.8%1.9%2.3%2.5%1.7%—
Buybacks as a share of market value1.7%-1.8%-0.2%2.8%-2.4%-0.8%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-16.5%-6.8%-2.1%
Operating income-6.1%13.2%-5.0%
Net income-11.5%9.0%-7.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin59.8%63.1%67.0%70.5%
Operating margin9.2%8.4%6.3%1.1%
Net margin6.7%6.6%4.9%-0.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings117.6184.1108.075.4—115.2-22.472.1-29.1124.1
Price to sales9.310.17.05.07.24.25.54.813.315.2

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 21 Jun 2024.

FY2024FY2017FY2014FY2013FY2011FY2010
Paid in the year0.050.040.040.0150.020.02
  • 2-for-1 split · 3 Apr 2014
  • 5-for-4 split · 18 Apr 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.